A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCL

Conditions

Lung

Phase 1B/2

What is the purpose of this trial?

The objective of this study is to investigate the safety, tolerability and antitumor activity of novel combination therapies administered in subjects with advanced EGFRm NSCLC.

  • Trial with
    MedImmune, Inc
  • Start Date
    06/13/2018
  • End Date
    11/25/2021
Trial Image

For more information about this study, contact:

Kira Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    08/30/2019
  • Study HIC
    #2000021942